Home » 干细胞新闻 » 环境带来的疾病或伤害 » CIRM grants $6.4 mn Strategic Partnership Award to Sangamo BioSciences to …

“Sangamo’s powerful and precise ZFN-genome editing technology enables modification of a patient’s own stem cells and potentially provides a safer approach to current therapies for haemoglobinopathies such as beta-thalassemia and sickle cell disease,” …
[Read more]

Comments are closed.

免费订阅最新信息

只需输入阁下之电邮地址,我们便会向定时你发送本站最新新闻及相关信息,费用全免。

联络我们

Name*

Email*

Tel

Message*

captcha

*require